Cargando…
Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies
Effective oncolytic virotherapy may require systemic delivery, tumor targeting, and resistance to virus-neutralizing (VN) antibodies. Since herpes simplex virus (HSV) glycoprotein D (gD) is the viral attachment/entry protein and predominant VN target, we examined the impact of gD retargeting alone a...
Autores principales: | Tuzmen, Ceren, Cairns, Tina M., Atanasiu, Doina, Lou, Huan, Saw, Wan Ting, Hall, Bonnie L., Cohen, Justus B., Cohen, Gary H., Glorioso, Joseph C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000558/ https://www.ncbi.nlm.nih.gov/pubmed/32042851 http://dx.doi.org/10.1016/j.omtm.2019.12.013 |
Ejemplares similares
-
Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021) -
The natural history of EGFR and EGFRvIII in glioblastoma patients
por: Heimberger, Amy B, et al.
Publicado: (2005) -
Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023) -
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
por: Padfield, Emily, et al.
Publicado: (2015) -
EGFRvIII: the promiscuous mutation
por: Greenall, Sameer A, et al.
Publicado: (2016)